AI Article Synopsis
- Bortezomib, a proteasome inhibitor, shows selective induction of apoptosis in breast cancer cells (specifically MDA-MB-231), contrary to its minimal effect on normal skin fibroblasts.
- In experiments, bortezomib treatment led to a significant, time-dependent increase in apoptosis, reaching up to 70% in both hypoxic and normoxic conditions for breast cancer cells.
- Unlike its effect on apoptosis, bortezomib did not induce senescence in breast cancer cells, suggesting its potential as a candidate for further research in breast cancer therapy.
Article Abstract
The cellular and molecular effects of the proteasome inhibitor-bortezomib-on breast cancer cells are as yet poorly characterised. Bortezomib selectively induces apoptosis in some cancer cells. However, the nature of its selectivity remains unknown. Previously, we demonstrated that: there was no effect of bortezomib action on apoptosis and a time-dependent increase in senescence of human skin fibroblasts. The study presented here provides novel information on cellular effects of bortezomib in breast cancer cells line MDA-MB-231. Our findings demonstrated that in contrast to normal fibroblasts, bortezomib treatment evoked a strong effect on apoptosis in breast cancer cells incubated in hypoxic and normoxic conditions. We observed a time-dependent increase up to 70 % in apoptosis of MDA-MB-231 cells in hypoxic and normoxic conditions. There was no effect of bortezomib action on senescence of these cells. We suggest that bortezomib may be candidates for further evaluation as chemotherapeutic agents for human breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950611 | PMC |
| http://dx.doi.org/10.1007/s11010-013-1939-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!